Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2018
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2018
SUMMARY
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Cervical Intraepithelial Neoplasia (CIN), Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Idiopathic CD4 Lymphocytopenia, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Non-Small Cell Lung Cancer, Sepsis, Sicca Syndrome (Sjogren), Solid Tumor, Squamous Cell Carcinoma, Transplant Rejection and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Cervical Intraepithelial Neoplasia (CIN), Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Idiopathic CD4 Lymphocytopenia, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Non-Small Cell Lung Cancer, Sepsis, Sicca Syndrome (Sjogren), Solid Tumor, Squamous Cell Carcinoma, Transplant Rejection and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
- The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
Genexine Inc
OSE Immunotherapeutics
Pfizer Inc
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXI-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06342674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
Featured News & Press Releases
May 29, 2018: NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.
May 07, 2018: OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas
Mar 08, 2018: New way to fight sepsis: Rev up patients immune systems
Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 14, 2017: OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministeriel" to Explore New Cytotoxic Antibodies
Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference
Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine
Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation
Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients
Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Non responders To Standard Of Care
Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting
May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
Genexine Inc
OSE Immunotherapeutics
Pfizer Inc
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXI-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06342674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
Featured News & Press Releases
May 29, 2018: NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.
May 07, 2018: OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas
Mar 08, 2018: New way to fight sepsis: Rev up patients immune systems
Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 14, 2017: OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministeriel" to Explore New Cytotoxic Antibodies
Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference
Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine
Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation
Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients
Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Non responders To Standard Of Care
Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting
May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Genexine Inc, H2 2018
Pipeline by OSE Immunotherapeutics, H2 2018
Pipeline by Pfizer Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Genexine Inc, H2 2018
Pipeline by OSE Immunotherapeutics, H2 2018
Pipeline by Pfizer Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Genexine Inc
OSE Immunotherapeutics
Pfizer Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Genexine Inc
OSE Immunotherapeutics
Pfizer Inc
